Pregnancy-Induced Sweet’s Syndrome Treated with Infliximab

Smolović, Brigita; Gajić-Veljić, Mirjana; Nikolić, Miloš; Muhović, D

doi:10.1159/000494974

Cited by 7 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The etiology of pregnancy-associated SS is unclear, although it has been speculated that hormonal changes during pregnancy are in some capacity immunomodulatory, thereby contributing to pregnancy-associated SS. Two cases of pregnancy-associated SS have been recently reported [22,23].…”

Section: Key Pointsmentioning

confidence: 99%

“…Recent case reports have also demonstrated efficacy for baricitinib (a Janus kinase inhibitor) [141], thalidomide [128], and combination acitretin and colchicine therapy [161]. A number of biologic agents have also been recently reported as viable management options for refractory SS: adalimumab [162] and infliximab [23,37,163] (anti-tumor necrosis factor alpha [TNFα] agents), anakinra [164] and rilonacept [91] (anti-IL1 agents), and tocilizumab (anti-IL6) [146,150]. Ustekinumab, an IL12 and IL23 inhibitor, was reported to be ineffective in a case of recalcitrant SS [165].…”

Section: Therapeutic Optionsmentioning

confidence: 99%

“…As reviewed by Heath and Ortega-Loayaza, a Th1 predominant response has been observed in SS. Recent reports of SS responding to the TNFα inhibitors adalimumab [162] and infliximab [23,37,163], and the IL-1 inhibitors anakinra [164] and rilonacept [91], support a Th1 axis bias.…”

Section: Cytokine and T-cell Dysregulationmentioning

confidence: 99%

See 2 more Smart Citations

New Practical Aspects of Sweet Syndrome

et al. 2022

View full text Add to dashboard Cite

Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, is an inflammatory, non-infectious skin reaction characterized clinically by tender, erythematous papules/plaques/pustules/nodules commonly appearing on the upper limbs, trunk, and head and neck; histologically, SS is characterized by dense neutrophilic infiltrate in the dermis. SS is accompanied by fever; an elevation of inflammatory markers (e.g., erythrocyte sedimentation rate, C reactive protein) in serum may also be observed. Although most cases of SS are idiopathic, SS also occurs in the setting of malignancy or following administration of an associated drug. SS has also been reported in association with pregnancy and a burgeoning list of infectious (most commonly upper respiratory tract infections) and inflammatory diseases; likewise, the litany of possible iatrogenic triggers has also grown. Over the past several years, a wider spectrum of SS presentation has been realized, with several reports highlighting novel clinical and histological variants. Corticosteroids continue to be efficacious first-line therapy for the majority of patients with SS, although novel steroid-sparing agents have been recently added to the therapeutic armamentarium against refractory SS. New mechanisms of SS induction have also been recognized, although the precise etiology of SS still remains elusive. Here, we catalogue the various clinical and histological presentations of SS, summarize recently reported disease associations and iatrogenic triggers, and review treatment options. We also attempt to frame the findings of this review in the context of established and emerging paradigms of SS pathogenesis.

show abstract

Section: Key Pointsmentioning

confidence: 99%

Section: Therapeutic Optionsmentioning

confidence: 99%

See 1 more Smart Citation

New Practical Aspects of Sweet Syndrome

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Sweet syndrome is frequently related to malignancies and chronic inflammatory disorders, and it can be caused by drugs as well. It can also be triggered by past infections or during pregnancy 3…”

Section: Introductionmentioning

confidence: 99%

Bullous Sweet syndrome as a presentation of chronic myelogenous leukaemia

2022

View full text Add to dashboard Cite

A woman in her 40s presented with a 3-month-long history of fever and tender erythematous bullous skin lesions not responsive to antibiotics. There had been no previous gastrointestinal, respiratory or urinary infection, nor did she have any history of autoimmune disease, drug reaction or vasculitis.Histological evaluation of skin biopsy showed diffuse dense neutrophilic infiltrates located in dermis diagnostic of Sweet syndrome. Haematological investigations showed leucocytosis with circulating immature cells, which on further investigations with bone marrow biopsy, were evident of chronic myelogenous leukaemia in the accelerated phase. Sweet syndrome was the presenting characteristic of chronic myelogenous leukaemia in this case, which is a rare association. Investigating unusual skin lesions can aid in the suspicion of underlying cancer, allowing for prompt action.

show abstract

“…Most of these individuals developed Sweet syndrome in association with chronic inflammatory bowel disease. [2][3][4][5][6] Our observation is the first to document the efficacy of this treatment in Marshall's syndrome, both for the inflammatory lesions and the elastolysis. Our findings should encourage early TNF-a inhibition by adalimumab as corticoid-sparing therapy in inflammatory dermatoses.…”

mentioning

confidence: 99%